地诺单抗一盒多少支？

(Denosumab), trade names Prolia and Xgeva, is a human monoclonal antibody, RANKL inhibitor, indicated for the treatment of osteoporosis, therapy-induced bone loss, metastasis to bone, and giant cell tumor of bone. Works by preventing the development of osteoclasts, cells that break down bone (bone resorption). Denosumab was developed by biotech company Amgen to reduce the risk of fractures in cancer patients. Denosumab is contraindicated in people with low blood calcium levels. The most common side effects of denosumab are joint and muscle pain in the arms or legs. Denosumab has been approved by the FDA and is included in NCCN guidelines.

Denosumab is currently approved for three indications: (1) Prevention of bone-related events in bone metastases from solid tumors, except for patients with multiple myeloma. Instructions for use: 120mg, once every 4 weeks. Also infuse calcium or vitamin D to prevent hypocalcemia. (2) Unresectable or surgical resection of giant cell tumor of bone in adults or bone-mature adolescents may cause serious complications. Instructions for use: 120mg, once every 4 weeks. In the first month of treatment, add 120mg on the 8th and 15th days respectively. (3) Hypercalcemia in bisphosphonate-resistant malignant tumors. The usage method is the same as the second indication.

Recommended usage and dosage of denosumab: (1) Denosumab can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

There are many different versions of denosumab, but no matter which version, its specifications are 1 tube/box of independent packaging to avoid collision or extrusion. The difference is that different versions of denosumab single injection contain different active ingredients per 1ml, which are divided into 60mg/120mg/125mg.